CNTA
Centessa Pharmaceuticals plc25.72
-0.43-1.64%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
3.80BP/E (TTM)
-Basic EPS (TTM)
-1.89Dividend Yield
0%Recent Filings
10-K
FY2025 results
Centessa Pharmaceuticals, a clinical-stage biotech, reported FY2025 ended December 31, 2025 with ongoing net losses as expected, burning cash on orexin agonist development while advancing cleminorexton through Phase 2a CRYSTAL-1 and Phase 1 trials. Q4 saw preliminary topline data from cleminorexton's 2-week crossover cohorts (n=55, cutoff September 23, 2025), showing dose-dependent MWT improvements (>20 min in NT1 1.5mg, p=0.0026) and 87% WCR reduction in NT1, with mild TEAEs like pollakiuria. No revenue or quarterly financials disclosed in the 10-K. Post-year-end, March 31, 2026 Transaction Agreement targets $38/share cash plus up to $9/share CVRs from Eli Lilly, closing Q3 2026 pending approvals. Cash runway undisclosed. Clinical delays threaten momentum.
8-K
Lilly acquires Centessa for $38 + CVRs
Centessa signed a deal on March 31, 2026, for Eli Lilly's subsidiary to acquire it via UK scheme of arrangement, paying $38 cash per share plus CVRs worth up to $9 on orexin drug approvals by 2029-2031. Boards approved; 20% shares locked via voting pacts. Closing hinges on 75% votes, court sanction, HSR clearance by Sept 2026. CVR payouts uncertain.
8-K
CEO Saha shifts to advisor role
Centessa Pharmaceuticals finalized its CEO transition on February 9, 2026, signing an advisory agreement with Saurabh Saha—effective after his January 1 exit—for hourly fees at $376 plus expenses over an initial six months. The separation deal accelerates equity vesting through February 2, grants a full 2025 target bonus pending approval, and extends exercise windows. Saha now advises only.
8-K
CEO transition to orexin expert
Centessa Pharmaceuticals appointed Dr. Mario Accardi, founder of its Orexin Program, as CEO effective January 1, 2026, succeeding Dr. Saurabh Saha, who steps down amicably to become advisor. Accardi, who led the 2021 Orexia acquisition, gets $600,000 base salary and $6M equity grant. Leadership shift aligns with orexin focus; ORX750 registrational program starts Q1 2026.
8-K
Expands ATM offering to $250M
Centessa Pharmaceuticals amended its sales agreement with Leerink Partners on November 24, 2025, enabling up to $250 million in at-the-market offerings of American Depositary Shares. Leerink earns up to 3.0% commission; no sales are required. Proceeds, if any, fund working capital and general purposes. Sales remain optional.
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
CNSP
CNS Pharmaceuticals, Inc.
7.39+0.12
CNTX
Context Therapeutics Inc.
1.10-0.03
CTNM
Contineum Therapeutics, Inc.
11.55-0.03
EPIX
ESSA Pharma Inc.
0.20+0.00
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
NVCT
Nuvectis Pharma, Inc.
7.69+0.04
ORKA
Oruka Therapeutics, Inc.
28.94-1.16
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00
TSHA
Taysha Gene Therapies, Inc.
5.82+0.06